|
|
OMB
APPROVAL
|
|
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB
Number:
|
3235-0058
|
|
Expires:
|
February
28, 2022
|
|
Estimated
average burden hours per response.
|
2.50
|
|
FORM
12b-25
|
SEC
FILE NUMBER
|
|
000-53223
|
|
|
|
|
|
CUSIP
NUMBER
|
|
NOTIFICATION
OF LATE FILING
|
|
(Check
one):
|
[_]
Form 10-K [_] Form 20-F [_] Form 11-K [X] Form 10-Q [_] Form 10-D
[_] Form N-CEN [_] Form N-CSR
|
|
|
|
For Period Ended:
|
June 30, 2021
|
|
|
[_] Transition Report on Form 10-K
[_] Transition Report on Form 20-F
[_] Transition Report on Form 11-K
[_] Transition Report on Form 10-Q
For the Transition Period Ended: ____________________
|
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
N/A
PART
I — REGISTRANT INFORMATION
|
MARIZYME, INC.
|
Full
Name of Registrant
|
|
N/A
|
Former
Name if Applicable
|
|
555 HERITAGE DRIVE, SUITE 205
|
Address
of Principal Executive Office (Street and Number)
|
|
JUPITER,
FLORIDA 33458
|
City,
State and Zip Code
|
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
[X]
|
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not
be filed within the prescribed time period. (Attach extra Sheets if Needed)
Marizyme,
Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report
on Form 10-Q for the quarterly period ended June 30, 2021 (the “Q2 2021 Form 10-Q”) by the prescribed due date for the reasons
described below.
Management
of the Company was unable to obtain the business information necessary to complete the preparation of the Company’s interim financial
statements for the three and six months ended June 30, 2021 as well as obtain the review of these financial statements by the Company’s
auditors in time for filing. Such information is required in order to prepare a complete filing. As a result of this delay, the Company
is unable to file its Quarterly Report on Form 10-Q within the prescribed time period without unreasonable effort or expense. The Company
expects to file within the extension period.
PART
IV — OTHER INFORMATION
|
|
|
|
|
|
(1)
|
Name
and telephone number of person to contact in regard to this notification
|
|
|
Dr.
Vithal Dhaduk
|
|
(561)
|
|
935-9955
|
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s).
|
|
|
Yes
[X] NO [_]
|
|
|
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof?
|
|
|
Yes
[_] NO [X]
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
|
MARIZYME,
INC.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
|
August
16, 2021
|
|
By:
|
/s/
Dr. Vithal Dhaduk
|
|
|
|
Name:
|
Dr.
Vithal Dhaduk
|
|
|
|
Title:
|
Principal
Executive and Accounting and Financial Officer
|
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of
the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by
an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of
the registrant shall be filed with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
Marizyme (QB) (USOTC:MRZM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marizyme (QB) (USOTC:MRZM)
Historical Stock Chart
From Apr 2023 to Apr 2024